Allergy Therapeutics, Allergy Therapeutics PLC (AIM:AGY, FRA:HHU)'s (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman join Proactive London's Katie Pilbeam about their results for the Year ended 30 June 2021.
The team explain their record pre-R&D operating profit which were ahead of market expectations which has been driven by continued sales growth.
Breaking down the key drivers, the successful ex-vivo VLP peanut biomarker study showed a 24-fold reduction in allergenicity and beneficial efficacy profile which is now paving the way for first-in-human trial in 2022.
Wykeman breaks down the numbers, with a strong cash balance of £40.3m providing sufficient funds with a small amount of debt under current assumptions to support Grass MATAL MPL pivotal Phase III field studies and Phase I VLP Peanut PROTECT trial.